CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM) accompanied by renal impairment (\[eGFR\] \< 40 mL/min). Enrolled subjects will receive three consecutive cycles of induction therapy with CM336 in combination with isatuximab.

NCT Number	NCT07585760
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
Enrollment	26 participants
Start Date	2026-07-25
Primary Completion	2028-05-01 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-02